An observational study in COVID-19 Pneumonia, sponsored by Ivan S Moiseev. Terminated at 2 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-22.
Sponsored by Ivan S Moiseev · Observational
This is an observational case-control study to evaluate COVID-19 vaccine effectiveness against hospitalisation with COVID-19 related conditions in St. Petersburg, Russia. Two sets of cases and control will be retrospectively analyzed to compare vaccination proportions and other characteristics to infer vaccine effectiveness from odds ratios. The first set of cases will be extracted from the data on hospitalisation of patients with COVID-19 to First Pavlov State Medical University of Saint-Petersburg hospitals, and controls will be patients hospitalised with other conditions. The second set of cases and controls will be based on patients referred to Medical Institute named after Berezin Sergey for computed tomography. Cases will be patients with positive SARS-CoV-2 status computed tomography confirmed pneumonia or patients referred to hospitalisation, and control will be patients without pneumonia and not referred to hospitalisation.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 182 is below the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Ivan S Moiseev is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Residents of Saint-Petersburg, Russia
Exclusion Criteria:
450 cases - patients hospitalised with COVID-19 450 control - patients hospitalised without COVID-19 in the same period (surgical, oncological, cardiological, ophthalmologic, gastroenterological departments)
Biological: COVID-19 Vaccines
Cases - patients with pneumonia confirmed after computed tomography. Controls - patients without pneumonia after computed tomography.
Biological: COVID-19 Vaccines
"Gam-COVID-Vac" "EpiVacCorona" "COVIVAC"
Effectiveness of full vaccination against hospitalization with COVID-19 pneumonia
Full vaccination effectiveness is calculated based on the odds ratio of vaccination proportions in cases and controls, adjusted for other patient characteristics. Full vaccination status is assigned after two weeks of the second dose for each vaccine separately.
Time frame: 3 months
Effectiveness of partial vaccination against hospitalization with COVID-19 pneumonia
Partial vaccination effectiveness is calculated based on the odds ratio of vaccination proportions in cases and controls, adjusted for other patient characteristics. Partial vaccination status is assigned after two weeks of the first dose for each vaccine separately.
Time frame: 3 months
Effectiveness of vaccination against hospitalization with COVID-19 pneumonia in different age groups
Evaluate vaccine effectiveness in different age groups (\<20, 20-29, 30-39, 40-49, 50-59, 60-69, \>70)
Time frame: 3 months
Plan to share: Undecided
This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ivan S Moiseev